Novel agents for multiple myeloma to overcome resistance in phase III clinical trials

Seminars in Oncology

Volumn 40, Issue 5, 2013, Pages 634-651

  Orlowski, Robert Z ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARFILZOMIB; CLARITHROMYCIN; DARATUMUMAB; DEHYDRODIDEMNIN B; DEXAMETHASONE; ELOTUZUMAB; IMATINIB; IXAZOMIB; IXAZOMIB CITRATE; LENALIDOMIDE; LORVOTUZUMAB MERTANSINE; MASITINIB; MELPHALAN; PANOBINOSTAT; PERIFOSINE; POMALIDOMIDE; PREDNISONE; PROTEASOME INHIBITOR; PX 171004; SILTUXIMAB; TABALUMAB; THALIDOMIDE; UNCLASSIFIED DRUG; VORINOSTAT;

ADD ON THERAPY; ANEMIA; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANOREXIA; ARTICLE; BACKACHE; CANCER PATIENT; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; COUGHING; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DISEASE COURSE; DRUG APPROVAL; DRUG BINDING; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HEADACHE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; IMMUNOMODULATION; LEUKOPENIA; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCULOSKELETAL PAIN; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; SIDE EFFECT; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WALDENSTROEM MACROGLOBULINEMIA;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; IMMUNOLOGIC FACTORS; INDOLES; MULTIPLE MYELOMA; OLIGOPEPTIDES; PHOSPHORYLCHOLINE; PROTEASOME INHIBITORS; REMISSION INDUCTION; THALIDOMIDE; THIAZOLES; TREATMENT OUTCOME;

EID: 84886935750     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2013.07.007     Document Type: Article

References (147)

1. P.G. Richardson, B. Barlogie, and J. Berenson A phase 2 study of bortezomib in relapsed, refractory myeloma N Engl J Med 348 26 2003 2609 2617
2. P.G. Richardson, P. Sonneveld, and M.W. Schuster Bortezomib or high-dose dexamethasone for relapsed multiple myeloma N Engl J Med 352 24 2005 2487 2498
3. R.Z. Orlowski, A. Nagler, and P. Sonneveld Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression J Clin Oncol 25 25 2007 3892 3901
4. J.F. San Miguel, R. Schlag, and N.K. Khuageva Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma N Engl J Med 359 9 2008 906 917
5. S. Singhal, J. Mehta, and R. Desikan Antitumor activity of thalidomide in refractory multiple myeloma N Engl J Med 341 21 1999 1565 1571
6. S.V. Rajkumar, E. Blood, D. Vesole, R. Fonseca, and P.R. Greipp Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group J Clin Oncol 24 3 2006 431 436
7. S.V. Rajkumar, L. Rosinol, and M. Hussein Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma J Clin Oncol 26 13 2008 2171 2177
8. D.M. Weber, C. Chen, and R. Niesvizky Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America N Engl J Med 357 21 2007 2133 2142
9. M. Dimopoulos, A. Spencer, and M. Attal Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma N Engl J Med 357 21 2007 2123 2132
10. D.S. Siegel, T. Martin, and M. Wang A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma Blood 120 14 2012 2817 2825
11. Vij R, Richardson PGG, Jagannath S, et al. Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): outcomes in pts refractory to lenalidomide (LEN) and/or bortezomib (BORT). J Clin Oncol. 2012;30(Suppl):abstr 8016
12. S.V. Rajkumar, S. Jacobus, and N.S. Callander Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial Lancet Oncol 11 1 2010 29 37
13. J.L. Harousseau, M. Attal, and H. Avet-Loiseau Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial J Clin Oncol 28 30 2010 4621 4629
14. M. Cavo, P. Tacchetti, and F. Patriarca Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study Lancet 376 9758 2010 2075 2085
15. P. Moreau, H. Avet-Loiseau, and T. Facon Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma Blood 118 22 2011 5752 5758
16. L. Garderet, S. Iacobelli, and P. Moreau Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation J Clin Oncol 30 20 2012 2475 2482
17. P.G. Richardson, E. Weller, and S. Jagannath Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma J Clin Oncol 27 34 2009 5713 5719
18. P.G. Richardson, E. Weller, and S. Lonial Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma Blood 116 5 2010 679 686
19. A.J. Jakubowiak, D. Dytfeld, and K.A. Griffith A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma Blood 120 9 2012 1801 1809
20. R. Niesvizky, T.G. Martin 3rd, and W. Bensinger Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma Clin Cancer Res 2013 In press
21. P.G. Richardson, C.C. Hofmeister, and D. Siegel MM-005: a phase 1, multicenter, open-label, dose-escalation study to determine the maximum tolerated dose for the combination of pomalidomide, bortezomib, and low-dose dexamethasone in subjects with relapsed or refractory multiple myeloma ASH Annual Meeting Abstracts 120 21 2012 727
22. J.J. Shah, E.A. Stadtmauer, and R. Abonour A multi-center phase I/II trial of carfilzomib and pomalidomide with dexamethasone (Car-Pom-d) in patients with relapsed/refractory multiple myeloma ASH Annual Meeting Abstracts 120 21 2012 74
23. S.K. Kumar, S.V. Rajkumar, and A. Dispenzieri Improved survival in multiple myeloma and the impact of novel therapies Blood 111 5 2008 2516 2520
24. H. Brenner, A. Gondos, and D. Pulte Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010 Haematologica 94 2 2009 270 275
25. B. Barlogie, M. Attal, and J. Crowley Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences J Clin Oncol 28 7 2010 1209 1214
26. S.Z. Usmani, J. Crowley, and A. Hoering Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured? Leukemia 27 1 2013 226 232
27. K.C. Anderson The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma J Clin Oncol 30 4 2012 445 452
28. R. Alexanian, K. Delasalle, M. Wang, S. Thomas, and D. Weber Curability of multiple myeloma Bone Marrow Res 2012 2012 916479
29. M. Othus, B. Barlogie, M.L. Leblanc, and J.J. Crowley Cure models as a useful statistical tool for analyzing survival Clin Cancer Res 18 14 2012 3731 3736
30. T. Hideshima, P.G. Richardson, and K.C. Anderson Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma Mol Cancer Ther 10 11 2011 2034 2042
31. A. Mahindra, J. Laubach, N. Raje, N. Munshi, P.G. Richardson, and K. Anderson Latest advances and current challenges in the treatment of multiple myeloma Nat Rev Clin Oncol 9 3 2012 135 143
32. D. Lavelle, Y.H. Chen, M. Hankewych, and J. DeSimone Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression Am J Hematol 68 3 2001 170 178
33. N. Mitsiades, C.S. Mitsiades, and P.G. Richardson Molecular sequelae of histone deacetylase inhibition in human malignant B cells Blood 101 10 2003 4055 4462
34. L. Catley, E. Weisberg, and Y.T. Tai NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma Blood 102 7 2003 2615 2622
35. C.S. Mitsiades, N.S. Mitsiades, and C.J. McMullan Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications Proc Natl Acad Sci U S A. 101 2 2004 540 545
36. X.Y. Pei, Y. Dai, and S. Grant Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors Clin Cancer Res 10 11 2004 3839 3852
37. S.T. Nawrocki, J.S. Carew, and M.S. Pino Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells Cancer Res 66 7 2006 3773 3781
38. T. Hideshima, J.E. Bradner, and J. Wong Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma Proc Natl Acad Sci U S A 102 24 2005 8567 8872
39. D.J. Kuhn, Z. Berkova, and R.J. Jones Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma Blood 120 16 2012 3260 3370
40. P. Richardson, C. Mitsiades, and K. Colson Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma Leuk Lymphoma 49 3 2008 502 507
41. A. Badros, A.M. Burger, and S. Philip Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma Clin Cancer Res 15 16 2009 5250 5257
42. D.M. Weber, T. Graef, and M. Hussein Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma Clin Lymphoma Myeloma Leuk 12 5 2012 319 324
43. D.S. Siegel, M.A. Dimopoulos, and S.-S. Yoon Vantage 095: vorinostat in combination with bortezomib in salvage multiple myeloma patients: final study results of a global phase 2b trial ASH Annual Meeting Abstracts 118 21 2011 480
44. M.A. Dimopoulos, S. Jagannath, and S.-S. Yoon Vantage 088: vorinostat in combination with bortezomib in patients with relapsed/refractory multiple myeloma: results of a global, randomized phase 3 trial ASH Annual Meeting Abstracts 118 21 2011 811
45. L. Catley, E. Weisberg, and T. Kiziltepe Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells Blood 108 10 2006 (3441-349)
46. P. Maiso, X. Carvajal-Vergara, and E.M. Ocio The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance Cancer Res 66 11 2006 5781 5789
47. E.M. Ocio, D. Vilanova, and P. Atadja In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma Haematologica 95 5 2010 794 803
48. E. Sanchez, J. Shen, and J. Steinberg The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo Leuk Res 35 3 2011 373 379
49. J.L. Wolf, D. Siegel, and H. Goldschmidt Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma Leuk Lymphoma 53 9 2012 1820 1823
50. S. Schmitt, A.D. Ho, and H. Goldschmidt The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide Onkologie 33 4 2010 183 186
51. J.F. San-Miguel, P.G.G. Richardson, and O. Sezer A phase lb study of oral panobinostat and IV bortezomib in relapsed or relapsed and refractory multiple myeloma J Clin Oncol 29 Suppl 2011 abstr 8075
52. J.F. San-Miguel, P. Moreau, and S.-S. Yoon Phase III study of panobinostat with bortezomib and dexamethasone in patients with relapsed multiple myeloma (PANORAMA 1) J Clin Oncol 30 Suppl 2012 abstr e18572
53. J.F. San-Miguel, V.T. de Moraes Hungria, and S.-S. Yoon Update on a phase III study of panobinostat with bortezomib and dexamethasone in patients with relapsed multiple myeloma: PANORAMA 1 ASH Annual Meeting Abstracts 118 21 2011 3976
54. R.Z. Orlowski, T.E. Stinchcombe, and B.S. Mitchell Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies J Clin Oncol 20 22 2002 4420 4427
55. J.J. Shah, and R.Z. Orlowski Proteasome inhibitors in the treatment of multiple myeloma Leukemia 23 11 2009 1964 1979
56. P. Moreau, P.G. Richardson, and M. Cavo Proteasome inhibitors in multiple myeloma: 10 years later Blood 120 5 2012 947 959
57. C.J. Kirk Discovery and development of second-generation proteasome inhibitors Semin Hematol 49 3 2012 207 214
58. K.M. Kortuem, and A.K. Stewart Carfilzomib Blood 121 6 2013 893 897
59. D.J. Kuhn, Q. Chen, and P.M. Voorhees Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma Blood 110 9 2007 3281 3290
60. S.D. Demo, C.J. Kirk, and M.A. Aujay Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome Cancer Res 67 13 2007 6383 6391
61. M.A. Hurchla, A. Garcia-Gomez, and M.C. Hornick The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects Leukemia 27 2 2013 430 440
62. S. Arastu-Kapur, J.L. Anderl, and M. Kraus Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events Clin Cancer Res 17 9 2011 2734 2743
63. O.A. O'Connor, A.K. Stewart, and M. Vallone A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies Clin Cancer Res 15 22 2009 7085 7091
64. M. Alsina, S. Trudel, and R.R. Furman A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma Clin Cancer Res 18 17 2012 4830 4840
65. Y.X. Zhu, E. Braggio, and C.X. Shi Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide Blood 118 18 2012 (4771-479)
66. A. Lopez-Girona, D. Mendy, and T. Ito Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide Leukemia 26 11 2012 2326 2335
67. K.M. Lee, J. Lee, and C.S. Park Cereblon inhibits proteasome activity by binding to the 20S core proteasome subunit beta type 4 Biochem Biophys Res Commun 427 3 2012 618 622
68. C.C. Bjorklund, W. Ma, and Z.Q. Wang Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide J Biol Chem 286 13 2011 11009 11120
69. C.C. Bjorklund, S.L. Aukerman, and A. Antonia Lopez-Girona Targeting the Wnt/β-catenin signaling pathway and CD44-mediated adhesion as a rational approach to overcome lenalidomide resistance in multiple myeloma Blood 2011 118 (abstr 928)
70. H. Aberle, A. Bauer, J. Stappert, A. Kispert, and R. Kemler beta-catenin is a target for the ubiquitin-proteasome pathway EMBO J 16 13 1997 3797 3804
71. K. Sukhdeo, M. Mani, and T. Hideshima beta-catenin is dynamically stored and cleared in multiple myeloma by the proteasome-aggresome-autophagosome- lysosome pathway Leukemia 26 5 2012 1116 1119
72. R. Vij, M. Wang, and J.L. Kaufman An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma Blood 119 24 2012 (5661-570)
73. R. Vij, D.S. Siegel, and S. Jagannath An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib Br J Haematol 158 6 2012 739 748
74. R. Hajek, R. Bryce, S. Ro, B. Klencke, and H. Ludwig Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM) BMC Cancer 12 2012 415
75. A.Z. Badros, K.P. Papadopoulos, N. Zojwalla, J.R.J. Lee, and D.S. Siegel A phase 1b study of 30-minute infusion carfilzomib 20/45 and 20/56 mg/m2 plus 40 mg weekly dexamethasone in patients with relapsed and/or refractory (R/R) multiple myeloma ASH Annual Meeting Abstracts 120 21 2012 4036
76. N. Lendvai, H. Landau, and A. Lesokhin Phase II study of infusional carfilzomib in patients with relapsed or refractory multiple myeloma ASH Annual Meeting Abstracts 120 21 2012 947
77. P. Moreau, H. Pylypenko, and S. Grosicki Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study Lancet Oncol 12 5 2011 431 440
78. E. Kupperman, E.C. Lee, and Y. Cao Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer Cancer Res 70 5 2010 1970 1980
79. D. Chauhan, Z. Tian, and B. Zhou In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells Clin Cancer Res 17 16 2011 5311 5321
80. Z. Tian, J.J. Zhao, and Y.T. Tai Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells Blood 120 19 2012 3958 3967
81. P.G. Richardson, R. Baz, and L. Wang Investigational agent MLN9708, an oral proteasome inhibitor, in patients (pts) with relapsed and/or refractory multiple myeloma (MM): results from the expansion cohorts of a phase 1 dose-escalation study ASH Annual Meeting Abstracts 118 21 2011 301
82. S. Kumar, W. Bensinger, and C.B. Reeder Weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients with relapsed and/or refractory multiple myeloma: results from a phase 1 dose-escalation study ASH Annual Meeting Abstracts 118 21 2011 816
83. S.K. Kumar, J.G. Berdeja, and R. Niesvizky A phase 1/2 study of weekly MLN9708, an investigational oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma (MM) ASH Annual Meeting Abstracts 120 21 2012 332
84. T. Latif, N. Chauhan, R. Khan, A. Moran, and S.Z. Usmani Thalidomide and its analogues in the treatment of multiple myeloma Exp Hematol Oncol 1 1 2012 27
85. S. Andhavarapu, and V. Roy Immunomodulatory drugs in multiple myeloma Expert Rev Hematol 6 1 2013 69 82
86. N. Saini, and A. Mahindra Novel immunomodulatory compounds in multiple myeloma Expert Opin Investig Drugs 22 2 2013 207 215
87. P.H. Schafer, A.K. Gandhi, and M.A. Loveland Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs J Pharmacol Exp Ther 305 3 2003 1222 1232
88. T. Hideshima, D. Chauhan, and Y. Shima Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy Blood 96 9 2000 2943 2950
89. S.A. Schey, P. Fields, and J.B. Bartlett Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma J Clin Oncol 22 16 2004 3269 3276
90. M.Q. Lacy, S.R. Hayman, and M.A. Gertz Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma J Clin Oncol 27 30 2009 5008 5014
91. M.Q. Lacy, S.R. Hayman, and M.A. Gertz Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM) Leukemia 24 11 2010 1934 1939
92. M.Q. Lacy, J.B. Allred, and M.A. Gertz Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease Blood 118 11 2011 2970 2975
93. Leleu X, Attal M, Arnulf B, et al. Pomalidomide plus low dose dexamethasone is active and well tolerated in bortezomib and lenalidomide refractory multiple myeloma: IFM 2009-02. Blood. 2013.
94. P.G. Richardson, D. Siegel, and R. Baz Phase I study of pomalidomide MTD, safety and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib Blood 2012
95. R. Vij, C.C. Hofmeister, and P.G. Richardson Pomalidomide (POM) with low-dose dexamethasone (LoDEX) in patients with relapsed and refractory multiple myeloma (RRMM): outcomes based on prior treatment exposure ASH Annual Meeting Abstracts 120 21 2012 4070
96. M.A. Dimopoulos, M.Q. Lacy, and P. Moreau Pomalidomide in combination with low-dose dexamethasone: demonstrates a significant progression free survival and overall survival advantage, in relapsed/refractory MM: a phase 3, multicenter, randomized, open-label study ASH Annual Meeting Abstracts 120 21 2012 LBA-6
97. I. Danylesko, K. Beider, A. Shimoni, and A. Nagler Monoclonal antibody-based immunotherapy for multiple myeloma Immunotherapy 4 9 2012 919 938
98. J. Yang, and Q. Yi Therapeutic monoclonal antibodies for multiple myeloma: an update and future perspectives Am J Blood Res 1 1 2011 22 33
99. Y.T. Tai, and K.C. Anderson Antibody-based therapies in multiple myeloma Bone Marrow Res 2011 2011 924058
100. M. Trikha, R. Corringham, B. Klein, and J.F. Rossi Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence Clin Cancer Res 9 13 2003 4653 4665
101. K. Bommert, R.C. Bargou, and T. Stuhmer Signalling and survival pathways in multiple myeloma Eur J Cancer 42 11 2006 1574 1580
102. P.M. Voorhees, Q. Chen, and D.J. Kuhn Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma Clin Cancer Res 13 21 2007 6469 6478
103. P.M. Voorhees, Q. Chen, and G.W. Small Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death Br J Haematol 145 4 2009 481 490
104. S.A. Hunsucker, V. Magarotto, and D.J. Kuhn Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma Br J Haematol 152 5 2011 579 592
105. H.C. van Zaanen, H.M. Lokhorst, and L.A. Aarden Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study Br J Haematol 102 3 1998 783 790
106. R. Kurzrock, P.M. Voorhees, and C. Casper Long-term safety in a phase 1 study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in patients with B-cell non-Hodgkin's lymphoma, multiple myeloma, or Castleman's disease ASH Annual Meeting Abstracts 118 21 2011 3959
107. A. Chari, H. Pri-Chen, and S. Jagannath Complete remission achieved with single agent CNTO 328, an anti-IL-6 monoclonal antibody, in relapsed and refractory myeloma Clin Lymphoma Myeloma Leuk 2013 In press
108. P.M. Voorhees, R.F. Manges, and P. Sonneveld A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma Br J Haematol 2013 In press
109. R.Z. Orlowski, L. Gercheva, and C. Williams Phase II, randomized, double blind, placebo-controlled study comparing siltuximab plus bortezomib versus bortezomib alone in pts with relapsed/refractory multiple myeloma J Clin Oncol 30 Suppl 2012 abstr 8018
110. Y.T. Tai, M. Dillon, and W. Song Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu Blood 112 4 2008 1329 1337
111. E.D. Hsi, R. Steinle, and B. Balasa CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma Clin Cancer Res 14 9 2008 2775 2784
112. F. van Rhee, S.M. Szmania, and M. Dillon Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma Mol Cancer Ther 8 9 2009 2616 2624
113. J.A. Zonder, A.F. Mohrbacher, and S. Singhal A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma Blood 120 3 2012 552 559
114. A.J. Jakubowiak, D.M. Benson, and W. Bensinger Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma J Clin Oncol 30 16 2012 1960 1965
115. S. Lonial, R. Vij, and T. Facon Phase I trial of elotuzumab, lenalidomide, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma J Clin Oncol 29 Suppl 2011 abstr 8076
116. P.G. Richardson, S. Jagannath, and P. Moreau A phase 2 study of elotuzumab (Elo) in combination with lenalidomide and low-dose dexamethasone (Ld) in patients (pts) with relapsed/refractory multiple myeloma (R/R MM): updated results ASH Annual Meeting Abstracts 120 21 2012 202
117. P. Dubreuil, S. Letard, and M. Ciufolini Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT PLoS One 4 9 2009 e7258
118. K.A. Hahn, G. Ogilvie, and T. Rusk Masitinib is safe and effective for the treatment of canine mast cell tumors J Vet Intern Med 22 6 2008 1301 1309
119. J.C. Soria, C. Massard, and N. Magne Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers Eur J Cancer 45 13 2009 2333 2341
120. A. Le Cesne, J.Y. Blay, and B.N. Bui Phase II study of oral masitinib mesilate in imatinib-naive patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST) Eur J Cancer 46 8 2010 1344 1351
121. C. Paul, B. Sans, and F. Suarez Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study Am J Hematol 85 12 2010 921 925
122. S. Georgin-Lavialle, L. Lhermitte, and F. Suarez Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor Eur J Haematol 89 1 2012 47 52
123. R.M. Lemoli, and A. Fortuna C-kit ligand (SCF) in human multiple myeloma cells Leuk Lymphoma 20 5-6 1996 457 464
124. A. Kalff, and A. Spencer The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies Blood Cancer J 2 2012 e89
125. M. Hallek, C. Neumann, and M. Schaffer Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines Exp Hematol 25 13 1997 1367 1377
126. M.S. Iqbal, N. Tsuyama, M. Obata, and H. Ishikawa A novel signaling pathway associated with Lyn, PI 3-kinase and Akt supports the proliferation of myeloma cells Biochem Biophys Res Commun 392 3 2010 415 420
127. A.M. Coluccia, T. Cirulli, and P. Neri Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib Blood 112 4 2008 1346 1356
128. J. Caers, E. Menu, and H. De Raeve Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic models of multiple myeloma Br J Cancer 98 12 2008 1966 1974
129. C.S. Mitsiades, E.M. Ocio, and A. Pandiella Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo Cancer Res 68 13 2008 5216 5225
130. M.V. Mateos, M.T. Cibeira, and P.G. Richardson Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma Clin Cancer Res 16 12 2010 3260 3269
131. T. Hideshima, L. Catley, and H. Yasui Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells Blood 107 10 2006 4053 4062
132. Y.Y. Shi, G.W. Small, and R.Z. Orlowski Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer Breast Cancer Res Treat 100 1 2006 33 47
133. T. Hideshima, L. Catley, and N. Raje Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells Br J Haematol 138 6 2007 783 791
134. C. Gajate, and F. Mollinedo Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts Blood 109 2 2007 711 719
135. E. David, R. Sinha, J. Chen, S.Y. Sun, J.L. Kaufman, and S. Lonial Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors Clin Cancer Res 14 16 2008 5090 5098
136. A.J. Jakubowiak, P.G. Richardson, and T. Zimmerman Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a phase I Multiple Myeloma Research Consortium study Br J Haematol 158 4 2012 472 480
137. P.G. Richardson, J. Wolf, and A. Jakubowiak Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial J Clin Oncol 29 32 2011 4243 4249
138. T. Plesner, H. Lokhorst, P. Gimsing, H. Nahi, S. Lisby, and Daratumumab Richardson PG A CD38 monoclonal antibody in patients with multiple myeloma - data from a dose-escalation phase I/II study ASH Annual Meeting Abstracts 120 21 2012 73
139. J.J. Shah, J.A. Zonder, and A.D. Cohen The novel KSP inhibitor ARRY-520 is active both with and without low-dose dexamethasone in patients with multiple myeloma refractory to bortezomib and lenalidomide: results from a phase 2 study ASH Annual Meeting Abstracts 120 21 2012 449
140. J.J. Shah, Da.M Weber, and Sa.K Thomas Phase 1 study of the novel kinesin spindle protein inhibitor ARRY-520 + carfilzomib in patients with relapsed and/or refractory multiple myeloma ASH Annual Meeting Abstracts 120 21 2012 4082
141. P.L. McCarthy, K. Owzar, and C.C. Hofmeister Lenalidomide after stem-cell transplantation for multiple myeloma N Engl J Med 366 19 2012 1770 1781
142. M. Attal, V. Lauwers-Cances, and G. Marit Lenalidomide maintenance after stem-cell transplantation for multiple myeloma N Engl J Med 366 19 2012 1782 1791
143. A. Palumbo, R. Hajek, and M. Delforge Continuous lenalidomide treatment for newly diagnosed multiple myeloma N Engl J Med 366 19 2012 1759 1769
144. M.V. Mateos, A. Oriol, and J. Martinez-Lopez Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial Blood 120 13 2012 2581 2588
145. A. Messori, D. Maratea, C. Nozzoli, and A. Bosi The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information Pharmacoeconomics 29 4 2011 269 285
146. J.G. Gaultney, W.K. Redekop, P. Sonneveld, and C.A. Uyl-de Groot Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value Expert Rev Anticancer Ther 12 6 2012 839 854
147. J.G. Gaultney, M.G. Franken, and S.S. Tan Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents J Clin Pharm Ther 38 1 2013 41 47